Prospective randomized evaluation of Graves disease treatment using 15 mCi or 30 mCi of radioiodine-131

• Grant number: 08/04504-5
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2008
• End date: July 31, 2010
• Field of knowledge: Health Sciences - Medicine - Medical Radiology
• Agreement: CNPq - PPSUS
• Principal Investigator: Marcelo Tatit Sapienza
• Grantee: Marcelo Tatit Sapienza
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Radioiodine therapy is an accepted alternative for the treatment of hyperthyroidism in Grave's disease. Its effects and indications have been extensively studied for more than 60 years, confirming it as a cost-effective and safe modality. Even though, the lack of a standardized treatment protocol leads to a variable patient response rate and to a lack of consensus about the ideal administered activity of iodine-131. So, a comparison of the effects of different radioiodine activities is of great concern. Comparison of the lowest and highest commonly administered activities of iodine-131 may allow a combination of a better dosimetry with a better clinical response. Objectives: The aim of this project is to compare the efficacy of 15 mCi and 30 mCi activities of iodine-131 in the treatment of hyperthyroidism in Grave's disease. Methods: Patients with hyperthyroidism due to Grave's disease and sent to the Nuclear Medicine section of the Radiology Institute of the "Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo" for radioiodine therapy will be randomized in two groups. Each group of patients will receive a fixed amount of iodine-131 - 15 mCi vs. 30 mCi. Other clinical and laboratorial variable that may influence therapy response will be stratified. Clinical-laboratorial data will be prospectively evaluated, with the tabulation and statistical analysis for the comparison of one year follow-up response of both groups. Each patient individually will be classified either as responders (euthyroidism or hypothiroidism) or non-responders (persistence of hyperthyroidism) to the treatment. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SAPIENZA, MARCELO TATIT; COURA-FILHO, GEORGE BARBERIO; WILLEGAIGNON, JOSE; WATANABE, TOMOCO; DUARTE, PAULO SCHIAVOM; BUCHPIGUEL, CARLOS ALBERTO. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of I-131. CLINICAL NUCLEAR MEDICINE, v. 40, n. 9, p. 715-719, SEP 2015. (08/04504-5)